Who we are?
The Directors
The Software Team
The Consulting Team
The Marketing & Admin Team
Meet the Directors
Dr Al G. Dossetter gained his Ph.D. from Nottingham University and after postdoctoral research at Harvard University joined AstraZeneca. He has 13 years of experience in medicinal chemistry spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors, and GPCR targets), and diabetes (obesity, GPCR, and enzyme inhibitors). In 2012, he cofounded MedChemica Limited to use matched molecular pair analysis to accelerate medicinal chemistry. The bulk of Al’s time is writing new software, on sales trips and working on consultancy projects. He has contributed to some of the 9 candidate drugs MedChemica has help develop with clients. Al is an enthusiastic advocate for science and is currently Chairman of the Society of Chemical Industry (SCI) Fine Chemical Group (FCG). In this role he helps organise conferences some 26 conferences every two years in the fields of Drug Design, Agrochemicals and Organic Synthesis.
Dr Al G. Dossetter gained his Ph.D. from Nottingham University and after postdoctoral research at Harvard University joined AstraZeneca. He has 13 years of experience in medicinal chemistry spread across oncology (hormonal and kinase inhibitors), inflammation (OA and RA, enzyme inhibitors, and GPCR targets), and diabetes (obesity, GPCR, and enzyme inhibitors). In 2012, he cofounded MedChemica Limited to use matched molecular pair analysis to accelerate medicinal chemistry. The bulk of Al’s time is writing new software, on sales trips and working on consultancy projects. He has contributed to some of the 9 candidate drugs MedChemica has help develop with clients. Al is an enthusiastic advocate for science and is currently Chairman of the Society of Chemical Industry (SCI) Fine Chemical Group (FCG). In this role he helps organise conferences some 26 conferences every two yeats in the fields of Drug Design, Agrochemicals and Organic Synthesis.
Dr Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals (then AstraZeneca) in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. Taking a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he cofounded MedChemica Ltd. He has played a significant role in algorithm generation and multiple consultancy projects helping client to produce some 9 clinical candidates. In recent years he has led the global medicinal chemistry effort to generate a SAR-CoV-2 inhibitor and new anti-virals for pandemic preparedness. He has taught medicinal chemistry courses at the University of Manchester and AstraZeneca courses in the U.K., France, and India. He is a named inventor on 18 patents and coauthored more than 20 articles, book chapters, and a textbook. His interests are in developing data driven methods to support decision making and medicinal chemistry education.
Dr Andrew G. Leach obtained his Ph.D. from the University of Cambridge and undertook postdoctoral research at UCLA, supported by the Fulbright scheme. He returned to the UK to join AstraZeneca as a computational chemist and worked in oncology, diabetes, and obesity. In 2012, he became one of the cofounders of MedChemica Limited and also joined Liverpool John Moores University as a lecturer in the School of Pharmacy and Biomolecular Sciences. Later he moved to Manchester university to continue his lecturing and research interests. These include all aspects of computation to support drug discovery and medicinal chemistry as well as the use of quantum mechanics to unravel interesting reaction mechanisms. He has published more the 70 articles, 5 book chapters and is a named inventor on 12 patents. Of the projects he worked on at AZ, capivasertib (AZD5363) was approved by the FDA in Dec 2023 (see publication).
Dr Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals (then AstraZeneca) in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas. Taking a secondment into the computational chemistry group, he co-developed matched molecular pair tools to quantify medicinal chemistry approaches. In 2012 he cofounded MedChemica Ltd. He has played a significant role in algorithm generation and multiple consultancy projects helping client to produce some 9 clinical candidates. In recent years he has led the global medicinal chemistry effort to generate a SAR-CoV-2 inhibitor and new anti-virals for pandemic preparedness. He has taught medicinal chemistry courses at the University of Manchester and AstraZeneca courses in the U.K., France, and India. He is a named inventor on 18 patents and coauthored more than 20 articles, book chapters, and a textbook. His interests are in developing data driven methods to support decision making and medicinal chemistry education.
Dr Andrew G. Leach obtained his Ph.D. from the University of Cambridge and undertook postdoctoral research at UCLA, supported by the Fulbright scheme. He returned to the UK to join AstraZeneca as a computational chemist and worked in oncology, diabetes, and obesity. In 2012, he became one of the cofounders of MedChemica Limited and also joined Liverpool John Moores University as a lecturer in the School of Pharmacy and Biomolecular Sciences. Later he moved to Manchester university to continue his lecturing and research interests. These include all aspects of computation to support drug discovery and medicinal chemistry as well as the use of quantum mechanics to unravel interesting reaction mechanisms. He has published more the 70 articles, 5 book chapters and is a named inventor on 12 patents. Of the projects he worked on at AZ, capivasertib (AZD5363) was approved by the FDA in Dec 2023 (see publication).